Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Transforming the oncology data paradigm by creating, capturing, and retrieving structured cancer data at the point of care: A Mayo Clinic pilot
Tevaarwerk, Amyé , Karam, Dhauna , Gatten, Clare A., Harlos, Elizabeth S., Maurer, Matthew J. , Haddad, Tufia C. , Stockham, Abigail L. , Leventakos, Konstantinos , Chen, Ruqin , Jochum, Jacob A., Schwecke, Anna, Eiring, Rachel A. , Carroll, Jamie L., Mandrekar, Sumithra J. , Tevaarwerk, Amye J , Holton, Sara J, Stockham, Abigail, Hubbard, Joleen M. , Mansfield, Aaron S , Halfdanarson, Thorvardur R , Schwecke, Anna S, Riaz, Irbaz Bin , McWilliams, Robert R , Galanis, Evanthia , Maurer, Matthew , Eiring, Rachel A , Giridhar, Karthik V. , Alberts, Steven R. , Holton, Sara J., Mansfield, Aaron S. , Hálfdánarson, Þorvarður R. , Carroll, Jamie M. , McWilliams, Robert R. , Galanis, Evanthia

Mayo Clinic

Cancer | April 25, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35304 | PMID 38662502 Get It

AbstractIntroductionStructured data capture requires defined languages such as minimal Common Oncology Data Elements (mCODE). This pilot assessed the feasibility of capturing 5 mCODE categories (stage, disease status, performance status (PS), intent of therapy and intent to change therapy).MethodsA tool (SmartPhrase) using existing and custom structured data elements was Built to capture 4 data categories (disease status, PS, intent of therapy and intent to change therapy) typically documented as free‐text within notes. Existing functionality for stage was supported by the Build. Participant survey data, presence of data (per encounter), and time in chart were collected prior to go‐live and repeat timepoints. The anticipated outcome was capture of >50% sustained over time without undue burden.ResultsPre‐intervention (5‐weeks before go‐live), participants had 1390 encounters (1207 patients). The median percent capture across all participants was 32% for stage; no structured data was available for other categories pre‐intervention. During a 6‐month pilot with 14 participants across three sites, 4995 encounters (3071 patients) occurred. The median percent capture across all participants and all post‐intervention months increased to 64% for stage and 81%–82% for the other data categories post‐intervention. No increase in participant time in chart was noted. Participants reported that data were meaningful to capture.ConclusionsStructured data can be captured (1) in real‐time, (2) sustained over time without (3) undue provider burden using note‐based tools. Our system is expanding the pilot, with integration of these data into clinical decision support, practice dashboards and potential for clinical trial matching.
118. Computer Vision In Hand Surgery: Validation Of A Practical And Scalable Application For Peripheral Nerve Functional Assessment
Rames, Jess D. , Tunaboylu, Mehmet Furkan , Emanuels, Andrew, Moran, Steven L.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 23, 2024 | Volume: 12 | Issue: S4 | Pages: 78-78

10.1097/01.gox.0001015560.73436.51 Get It

Abstract 9213: Effect of Ai-Enabled Ecg Screening for Low Ef in Patients With Different Socioeconomic Status
Inselman, Jonathan , Rushlow, David , Thacher, Thomas D., Behnken, Emma , Bernard, Matthew , Rosas, Steven , Akfaly, Abdulla , Misra, Artika , Molling, Paul , Krien, Joseph, Siontis, Konstantinos C. , Friedman, Paul, Kurani, Shaheen , McCoy, Rozalina G. , Foss, Randy , Barry, Barbara , Kapa, Suraj , Gersh, Bernard J. , Pellikka, Patricia A. , López-Jiménez, Francisco , Attia, Zachi I. , Halamka, John , Noseworthy, Peter A. , Yao, Xiaoxi

Mayo Clinic

Circulation | April 23, 2024 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.9213 Get It

Introduction: Asymptomatic LV systolic dysfunction is often underdiagnosed, leading to missed opportunities for treatment. In a recently completed pragmatic RCT, an AI algorithm performed on the ECGs ordered as part of routine practice increased early diagnosis of low EF. The current study aimed to understand whether the effectiveness of the AI algorithm integrated into routine care differed by the socioeconomic status of the patient. Methods: The main findings of the RCT were previously published. Clinicians in the intervention group had access to AI results (i.e., a positive or negative screening result, with positive results indicating a high likelihood of low EF). When a positive result was found, clinicians in the intervention group received an alert that encouraged them to order TTE if considered clinically appropriate. Clinicians in the control group did not have access or received alerts. Area deprivation index (ADI) was used to measure area-level social determinants of health. This study included 16,992 patients (control 8,225; intervention: 8,767) who had ECG performed for any indications between 8/5/2019 and 3/31/2020, no prior HF, and a valid address to derive ADI. The primary endpoint was a new diagnosis of EF≤50% within 3 months. Results: The mean age was 60.5±17.6 y. AI increased the diagnosis of low EF in the overall cohort (OR 1.42 [1.13, 1.78], p=0.01). The magnitude of benefit was greater in patients with higher socioeconomic status, e.g., living in an area that is less deprived (OR 1.88 [1.16, 3.05]), with higher median income, lower poverty rate, higher education level, better housing conditions, and higher proportion of white-collar workers, although the interaction was not statistically significant (Figure). Conclusions: AI enables early diagnosis of low EF and the magnitude of benefit might be numerically greater in patients with higher socioeconomic status, possibly due to variations in access to or referral for subsequent testing.
Abstract 14260: Suppression and Replacement Gene Therapy for Type 2 Long QT Syndrome
Dotzler, Steven M. , Zhou, Wei, Kim, CS John, Tester, David J. , Ackerman, Michael J. , Bains, Sahej

Mayo Clinic

Circulation | April 23, 2024 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.14260 Get It

Introduction: Type 2 long QT syndrome (LQT2) is caused by loss-of-function variants in the KCNH2 -encoded K v 11.1 potassium channel which is essential for the rapid delayed rectifier channel (I Kr ) that governs phase 3 of cardiac action potential (AP). No current therapies target the molecular cause of LQT2. Methods: A dual-component “suppression-and-replacement” (SupRep) KCNH2 gene therapy was created by cloning into a single construct a custom-designed KCNH2 shRNA that produces ~80% knockdown (suppression) and a “shRNA-immune” (shIMM) KCNH2 cDNA modified by the introduction of synonymous single nucleotide substitutions within the shRNA target site (replacement). The ability of KCNH2-SupRep gene therapy to suppress and replace LQT2-causative variants in KCNH2 was evaluated via heterologous expression in TSA201 cells. Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) were generated from two patients with LQT2 (KCNH2-G604S and -N633S). CRISPR-Cas9 corrected isogenic control iPSC-CMs were made. Both lines were treated with KCNH2-SupRep or non-targeting control shRNA (shCT). FluoVolt voltage dye was used to measure the APD. Results: KCNH2-SupRep achieved mutation-independent suppression of wild-type KCNH2 and both LQT2-causative variants with simultaneous replacement of KCNH2-shIMM as measured by allele-specific qRT-PCR. Treatment with KCNH2-SupRep resulted in shortening of the pathologically prolonged APD at 90% repolarization (APD 90 ) to near isogenic control APD 90 levels (G604S: isogenic controls, 424 + 39 ms and N633S: isogenic controls, 433 + 16 ms) compared to treatment with non-targeting shCT (G604S: SupRep treated, 399±105 ms vs. shCT treated, 577±39 ms, p<0.0001; N633S: SupRep treated, 432±85 ms vs. shCT treated, 483±65 ms, p<0.005). Conclusions: We provide the first proof-of-principle gene therapy for correction of LQT2. Like our sentinel discovery of SupRep gene therapy for LQT1, KCNH2-SupRep successfully suppressed and replaced KCNH2 to normal wild-type levels. In TSA201 cells, co-transfection of LQT2 variants and KCNH2-SupRep caused mutation-independent suppression-and-replacement of KCNH2 . In LQT2 iPSC-CMs, KCNH2-SupRep shortened the APD, thereby eliminating the pathognomonic feature of LQT2.
Abstract 9379: Biomarkers of Aortic Stenosis Severity
Blackshear, Joseph L., Safford, Robert E. , Ung, Steven, Misiri, Juna, Johns, Gretchen S., Mufuka, Gabriel B, Parikh, Pragnesh , Al-Omari, Malik A., Chen, Dong

Mayo Clinic

Circulation | April 23, 2024 | Volume: 124 | Issue: suppl_21 | Pages: No page available

10.1161/circ.124.suppl_21.a9379 Get It

Aortic stenosis (AS) requires repeat assessments to optimally time intervention. The utility of laboratory tests to complement clinical and hemodynamic assessments has not been established. We assessed clinical, echocardiographic, and laboratory data in 76 patients with AS or heart valve replacement (HVR), age 77 years, 37% women. Laboratory assessments included von Willebrand factor (VWF) antigen, activity, (Act/Ag, normal > 0.8), VWF multimer distribution (abnormal=loss of highest molecular weight multimers=Mult+), brain natriuretic peptide (BNP, abnormal > 155 pg/ml=BNP+), and platelet function analyzer 100 collagen-ADP closure time (PFA, normal < 121 seconds). Table: Coefficients of correlation, r, and F statistic. Chi-square, and probability. Correlation of BNP to mean gradient in patients with GFR>60 remained poor, r=0.29, while for PFA r = 0.65. Median (IQR) for PFA and BNP for mild, moderate, and severe AS and HVR are shown below. VWF multimers were abnormal in 3/14 mild AS, 6/14 moderate AS, 22/25 severe AS and 4/23 HVR patients. The severity of AS was most strongly associated with VWF multimer abnormality and prolonged PFA closure time, weakly with BNP, and not with VWF Act/Ag. Conclusion: Among various laboratory measures, PFA and VWF multimers are strongly associated with AS severity, and may merit assessment as complementary diagnostic and prognostic biomarkers in AS.
Democratizing Artificial Intelligence in Anatomic Pathology
Flotte, Thomas J. , Derauf, Stephanie A., Byrd, Rachel K., Kroneman, Trynda, Bell, Debra A., Stetzik, Lucas, Lee, Seung‐Yi , Samiei, Alireza, García, Joaquín J. , Beamer, Gillian , Kroneman, Trynda N, Hart, Steven N. , Westerling-Bui, Thomas

Mayo Clinic

Archives of Pathology & Laboratory Medicine | April 22, 2024 | Volume: 149 | Issue: 1 | Pages: 55-59

10.5858/arpa.2023-0205-oa | PMID 38649149 Get It

Context.— Artificial intelligence is a transforming technology for anatomic pathology. Involvement within the workforce will foster support for algorithm development and implementation. Objective.— To develop a supportive ecosystem that enables pathologists with variable expertise in artificial intelligence to create algorithms in a development environment with seamless transition to a production environment. Design.— Platform requirements included (1) approachable and intuitive user interface, (2) diverse algorithmic modeling options, (3) support capability for internal and external collaborations, (4) a seamless mechanism for discovery to clinical deployment transition, (5) the ability to meet minimum institutional requirements for information technology (IT) review, and (6) the ability to be scalable over time. The ecosystem required platform education, data science guidance, project management structure, and ongoing leadership. Results.— The development team considered internal development and vended solutions. Because of the extended timeline and resource requirements for internal development, a decision was made to use a vended solution. Vendor proposals were solicited and reviewed by pathologists, IT, and security groups. A vendor was selected and pipelines for development and production were established. Proposals for development were solicited from the pathology department. Eighty-four investigators were selected for the initial cohort, receiving training and access to dedicated subject matter experts. A total of 30 of 31 projects progressed through the model development process of annotating, training, and validation. Based on these projects, 15 abstracts were submitted to national meetings. Conclusions.— Democratizing artificial intelligence by creating an ecosystem to support pathologists with varying levels of expertise can break down entry barriers, reduce overall cost of algorithm development, improve algorithm quality, and enhance the speed of adoption.
Applying a Health Equity Lens to Intraoperative Opioid Administration and Postoperative Pain
Milam, Adam J. , Youssef, Mohanad R. , Ugochukwu, Kenechukwu, Hanson, Kristine T. , Raynor, Gwendolyn, Milam, Adam J , Hanson, Kristine , Habermann, Elizabeth B. , Brennan, Emily , Porter, Steven B. , Harbell, Monica W. , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | April 19, 2024 | Volume: 139 | Issue: 3 | Pages: 675-678

10.1213/ane.0000000000006968 | PMID 38640079 Get It

Cell‐based tissue engineered flexor tendon allograft: A canine in vivo study
Lin, Subin, Reisdorf, Ramona L., Lu, Chun Kuan, An, Kai‐Nan, Moran, Steven L. , Amadio, Peter C. , Zhao, Chunfeng , Reisdorf, Ramona, Wang, Zhanwen , Amadio, Peter C , Zhao, Chunfeng , An, Kai‐Nan

Mayo Clinic

Journal of Orthopaedic Research | April 19, 2024 | Volume: 42 | Issue: 9 | Pages: 1923-1932

10.1002/jor.25854 | PMID 38639414 Get It

AbstractThis study aimed to compare the clinically established autologous extrasynovial tendon graft to a newly developed tissue‐engineered allograft (Eng‐allograft) in terms of functional outcomes following flexor tendon reconstruction in a canine model. The second and fifth flexor digitorum profundus (FDP) tendons from 16 dogs were transected and repaired in Zone II. After 6 weeks of cage activity, the repaired tendons were intentionally ruptured, creating a clinically relevant model for reconstruction. The re‐ruptured FDP tendons were then reconstructed using either the clinically standard autologous extrasynovial tendon graft or the Eng‐allograft, which had been revitalized with autologous bone marrow‐derived mesenchymal stem cells (BMSCs) and synovialized using carbodiimide derivatized synovial fluid (cd‐SYN). Following 12 weeks of postoperative rehabilitation, the functional outcomes of the surgical digits were evaluated. The Eng‐allograft group exhibited improved digital function, including lower digit work of flexion and reduced adhesion status, while maintaining similar tendon gliding resistance compared to the autograft group. However, the failure load of both the distal and proximal host/graft conjunctions in the Eng‐allograft group was significantly lower than that of the autograft group with higher graft rupture at the host−graft junction. In conclusion, the decellularized allogenic intrasynovial tendon, when revitalized BMSCs and synovialized with cd‐SYN, demonstrates positive effects on digital function improvement and adhesion reduction. However, the healing at both proximal and distal graft/host junctions is far lower than the autograft. Further research is needed to enhance the healing capacity of allograft conjunctions, aiming to achieve a comparable level of healing seen with autografts.
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
Buch, Maya H , Bhatt, Deepak L. , Charles‐Schoeman, Christina , Giles, Jon T. , Koch, Gary G., Ytterberg, Steven R. , Nagy, Edward, Jo, Hyejin, Connell, Carol A., Masri, Karim R. , Yndestad, Arne, Ytterberg, Steven, Masri, Karim Richard , Bhatt, Deepak L , Giles, Jon T , Mikuls, Ted R. , Kwok, Kenneth

Mayo Clinic

RMD Open | April 12, 2024 | Volume: 10 | Issue: 2 | Pages: e003912

10.1136/rmdopen-2023-003912 | PMID 38609322 Get It

Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral Rheumatoid Arthritis Trial (ORAL) Surveillance. Methods Patients with RA aged ≥50 years and with ≥1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day or TNFi. MACE (non-fatal myocardial infarction (MI), non-fatal stroke or CV death (MACE-3)) was extended by sequential addition of CV events (hospitalisation for unstable angina (MACE-4), coronary revascularisation (MACE-5), transient ischaemic attack (MACE-6), peripheral vascular disease (MACE-7)), heart failure (HF) hospitalisation (MACE-8) and venous thromboembolism (VTE; (MACE-8 plus VTE)). HRs (tofacitinib vs TNFi) were evaluated for MACE and individual components. Results HRs for MACE-4 to MACE-8 with combined and individual tofacitinib doses versus TNFi were similar. Risk of MACE-8 plus VTE appeared similar with tofacitinib 5 mg two times per day versus TNFi (HR 1.12 (0.82 to 1.52)), but higher with tofacitinib 10 mg two times per day versus TNFi (HR 1.38 (1.02 to 1.85)). Risk of MI was higher with tofacitinib versus TNFi, but difference in risk of other individual CV events was not suggested. Across extended MACE definitions, risk appeared higher with tofacitinib versus TNFi in those with atherosclerotic CV disease or age ≥65 years. Conclusion In ORAL Surveillance, risk of composite CV endpoints combining all ischaemic CV events and HF did not appear different with tofacitinib versus TNFi. The totality of CV risk was higher with tofacitinib 10 mg two times per day versus TNFi, driven by an increase in VTE. Trial registration number NCT02092467.
Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
Masri, Ahmad , Lester, Steven J., Stendahl, John C. , Hegde, Sheila M. , Sehnert, Amy J. , Balaratnam, Ganesh, Fox, Shawna, Wang, Andrew , Wang, Andrew , Sehnert, Amy J , Hegde, Sheila M , Shah, Ashish

Mayo Clinic

Journal of the American Heart Association | April 9, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.030607 | PMID 38591260 Get It

Background The phase 2 PIONEER‐HCM (Phase 2 Open‐label Pilot Study Evaluating Mavacamten in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) study showed that mavacamten improved left ventricular outflow tract gradients, exercise capacity, and symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM), but the results of longer‐term treatment are less well described. We report interim results from the PIONEER‐OLE (PIONEER Open‐Label Extension) study, the longest‐term study of mavacamten in patients with symptomatic obstructive HCM. Methods and Results Patients who previously completed PIONEER‐HCM (n=20) were eligible to enroll in PIONEER‐OLE. Patients received oral mavacamten, 5 mg once daily (starting dose), with individualized dose titration at week 6. Evaluations included serial monitoring of safety, echocardiography, Kansas City Cardiomyopathy Questionnaire–Overall Summary Score, and serum NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels. Thirteen patients enrolled and received mavacamten (median study duration at data cutoff, 201 weeks). Most patients (92.3%) received β‐blockers concomitantly. Treatment‐emergent adverse events were predominantly mild/moderate. One patient had an isolated reduction in left ventricular ejection fraction to 47%, which recovered and remained normal with continued treatment at a reduced dose. At week 180, mavacamten was associated with New York Heart Association class improvements from baseline (class II to I, n=9; class III to II, n=1; and unchanged, n=2), sustained reductions in left ventricular outflow tract gradients (mean [SD] change from baseline: resting, −50 [55] mm Hg; Valsalva, −70 [41] mm Hg), and serum NT‐proBNP levels (median [interquartile range] change from baseline: −498 [−2184 to −76] ng/L), and improved Kansas City Cardiomyopathy Questionnaire–Overall Summary Score (mean [SD] change from baseline: +17 [16]). Conclusions This long‐term analysis supports the continued safety and effectiveness of mavacamten for >3 years in obstructive HCM. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03496168.